What is Immunoactiva?
Operating as a specialized entity within the Custom Software and IT Services industry, Immunoactiva has cultivated a reputation for delivering high-value technical solutions. With a lean team of 10 to 19 professionals and annual revenues ranging between 1M and 5M, the company demonstrates significant operational efficiency. Its core competency lies in bridging the gap between complex enterprise requirements and scalable digital infrastructure, a niche that has proven resilient despite broader market fluctuations. By maintaining a focused service model, Immunoactiva continues to drive value for its client base while optimizing its internal resource allocation.
How much funding has Immunoactiva raised?
Immunoactiva has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Immunoactiva
PPP
Public-Private Partnership
What's next for Immunoactiva?
The recent influx of capital serves as a catalyst for the next phase of the company's growth strategy. Given the context of this large-scale late-stage funding, Immunoactiva is expected to prioritize the expansion of its service delivery capabilities and the enhancement of its proprietary software frameworks. Strategic initiatives will likely focus on scaling human capital and deepening technical expertise to capture a larger share of the enterprise IT services market. As the firm transitions into this mature growth phase, the focus will shift toward long-term sustainability and the potential for further market penetration through targeted service diversification and enhanced client acquisition strategies.
See full Immunoactiva company page
